CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) In Thousands, except Share data, unless otherwise specified	12 Months Ended		101 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2012
OPERATING EXPENSES
General and administrative	$ 1,764	$ 3,506	$ 31,486
Research and development	2,385	6,394	102,434
Purchased in-process research and development	0	0	34,311
Other	0	0	(375)
Total operating expenses	4,149	9,900	167,856
Interest and other income, net	(96)	(31)	(13,854)
Loss from continuing operations before taxes	4,053	9,869	154,002
Income tax benefit	0	(158)	(1,355)
Loss from continuing operations	4,053	9,711	152,647
Discontinued operations - net gain on sale of the bone device business, net of taxes of $267	0	0	(2,202)
Net Loss	4,053	9,711	150,445
Less: Net Loss attributable to the noncontrolling interest	(473)	0	(473)
Net Loss attributable to Capstone Therapeutics Corp. stockholders	$ 3,580	$ 9,711	$ 149,972
Per Share Information:
Net loss, basic and diluted, attributable to Capstone Therapeutics Corp. stockholders (in dollars per share)	$ 0.09	$ 0.24
Basic and diluted shares outstanding (in shares)	40,879	40,775